Why the study?
NAFLD is highly prevalent with complex pathogenesis, and the function and regulatory mechanism of miR-625-5p in NAFLD remained to be elucidated.
Does miR-625-5p overexpression reduce lipid accumulation, inflammatory response, and liver damage in NAFLD models?
Population
112 patients with NAFLD, 106 control subjects, and HepG2 and THLE-2 cells
Comparison
NAFLD vs control subjects and miR-625-5p overexpression vs controls in cell models
Design
Case-control and in vitro translational study
Key result
MiR-625-5p expression was significantly downregulated in patients with NAFLD compared to controls, suggesting its potential as a diagnostic biomarker.
Authors
Loading...
Supports miR-625-5p as candidate NAFLD biomarker; hypothesis-generating for therapeutic targeting, requires prospective validation.
Case-Control (n=218)
Does miR-625-5p overexpression reduce lipid accumulation, inflammatory response, and liver damage in NAFLD models?
MiR-625-5p is downregulated in NAFLD and its overexpression impedes lipid accumulation and liver damage in vitro by targeting CCND1, suggesting potential as a biomarker and therapeutic target.
Fan et al. (2026) conducted a case-control in Non-alcoholic fatty liver disease (NAFLD) (n=218). miR-625-5p expression vs. Control subjects was evaluated on Diagnostic value of miR-625-5p for NAFLD. MiR-625-5p expression was significantly downregulated in patients with NAFLD compared to controls, suggesting its potential as a diagnostic biomarker.